[NEUROPROTECTIVE EFFECT OF AMINOGUANIDINE IN EXPERIMENTAL OBSTETRIC ANTIPHOSPHOLIPID SYNDROME].

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Antiphospholipid syndrome (APS) during pregnancy is associated with increased autoantibodies and oxidative stress in the brain.
• Glial fibrillary acidic protein (GFAP) and nitric oxide (NO) synthesis are key markers of neuroinflammation and neuronal damage in APS.

Purpose of the Study:

• To investigate the neuroprotective effects of aminoguanidine in a mouse model of obstetric antiphospholipid syndrome.
• To assess aminoguanidine's impact on autoantibodies, NO synthesis, GFAP levels, and oxidative stress markers in the cerebral hemispheres.

Main Methods:

• BALB/c mice with APS on day 18 of pregnancy were treated with aminoguanidine.
• Serum autoantibodies, GFAP content (total and specific fragments), nitrite/nitrate (NO2¯/NO3¯), and markers of lipid peroxidation and antioxidant activity were measured.

Main Results:

• APS mice showed elevated autoantibodies, GFAP, NO metabolites, and oxidative stress.
• Aminoguanidine treatment reduced specific autoantibodies (120 kDa, 150 kDa) and attenuated oxidative stress and lipid peroxidation.
• Aminoguanidine increased antioxidant system activity and content, with selective effects on GFAP fragments.

Conclusions:

• Aminoguanidine exhibits significant neuroprotective properties in obstetric APS.
• The drug mitigates key pathological processes including autoantibody production and neuroinflammation.
• Aminoguanidine represents a potential therapeutic agent for managing APS-related neurological complications in pregnancy.